This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A composition useful for hepatoprotection, said composition comprising an effective amount of a polar solvent extract (A001) from the plant *Cryptolepis buchanani*; and optionally pharmaceutically acceptable additives.

2. (currently amended) The composition as claimed in claim 1, wherein said additives are selected from a group of nutrients consisting ~~essentially~~ of proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, and starch-gelatin paste; and/or a pharmaceutically acceptable carrier, excipient, diluent, or solvent.

3. (currently amended) The composition as claimed in claim 1, wherein the polar solvent is selected from a group consisting ~~essentially~~ of alcohol, rectified spirit, aqueous rectified spirit, and water.

4. (previously presented) The composition as claimed in claim 1, wherein said extract and additives are in the ratio ranging between 1:1 to 1:10.

5. (currently amended) A method of preparing a polar solvent extract A001 and its four fractions F001, F002, F003, and F004 from plant *Cryptolepis buchanani* having hepatoprotective activity, said method comprising:

(i) powdering said plant,

(ii) percolating said powder in cold with a polar solvent,

(iii) concentrating said percolate to prepare a polar solvent extract (A001),

(iv) triturating said extract successively with solvents of increasing polarity using hexane and chloroform,

(v) collecting fractions F001 and F002 respectively with said solvents and a residue,

(vi) partioning said residue between n-butanol and water of ratio 5:1, and

(vii) collecting the n-butanol soluble fraction (F003) and the water soluble fraction (F004).

6. (previously presented) The method as claimed in claim 5, wherein a root and an aerial part of said plant are preferred plant parts for said activity.

7. (currently amended) The method as claimed in claim 5, wherein polar solvent is selected from a group consisting ~~essentially~~ of methanol, propanol, and ethanol.

8. (previously presented) The method as claimed in claim 5, wherein the polar solvent is 95% ethanol.

9. (previously presented) The method as claimed in claim 5, wherein the percolated plant in polar solvent is at a concentration ranging between 100 and 500gms/liter.

10. (previously presented) The method as claimed in claim 5, wherein the percolation is for a time duration ranging between 14 and 18 hours.

11. (previously presented) The method as claimed in claim 5, wherein the percolated extract is concentrated by evaporation under reduced pressure.

12. (previously presented) The method as claimed in claim 5, wherein the percolated extract is concentrated at a temperature ranging between 40° C and 50° C.

13. (previously presented) The method as claimed in claim 5, wherein the percolated extract is concentrated at a temperature of about 45° C.

14. (previously presented) The method as claimed in claim 5, wherein the percolated extract is finally dried in a vacuum.

15. (previously presented) The method as claimed in claim 5, wherein the trituration rate ranges between 15 and 35 ml/minute.

16. (previously presented) The method as claimed in claim 5, wherein the trituration rate is about 23 ml/minute.

17. (previously presented) The method as claimed in claim 5, wherein triturating with each of the said solvents occurs for a time duration ranging between 20 and 40 minutes.

18. (previously presented) The method as claimed in claim 5, wherein said fractions have a concentration of :

(a) F001– about 11% (w/w),

(b) F002 – about 15 % (w/w),

(c) F003 — about 40% (w/w), and

(d) F004 — about 35% (w/w).

19. (previously presented) A composition useful for hepatoprotection, said composition comprising an effective amount of the fraction F003 of claim 5 from plant *Cryptolepis buchanani*, and optionally pharmaceutically acceptable additives.

20. (currently amended) The composition as claimed in claim 19, wherein said additives are selected from a group of nutrients consisting ~~essentially~~ of proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, and starch-gelatin paste; and/or a pharmaceutically acceptable carrier, excipient, diluent, or solvent.

21. (previously presented) The composition as claimed in claim 19, wherein said fraction and additives are in a ratio ranging between 1:1 and 1:10.

22-34. (cancelled)